In the field of tumors, any breakthrough is not easy.

Although humans have discovered cancer for a long time, chemotherapy has long been the core treatment method. Of course, after countless failures and dashed hopes, once there is a breakthrough, the progress is often unexpected.

For example, after decades of silence, the treatment of small cell carcinoma seems to have ushered in a period of accelerated breakthroughs.

On August 15, AstraZeneca announced that its drug durvalumab has been accepted by the FDA for the indication of limited small cell lung cancer (LS-SCLC). If approved for marketing, this will be the first immunotherapy in 40 years to show survival benefits in this field, representing an important breakthrough.

For limited-stage SCLC, the current first-line treatment is still chemoradiotherapy, especially the treatment of cisplatin combined with etoposide, which occupies an absolute dominant position in treatment.

Amgen has also made progress in the field of small cell lung cancer. Its DLL3/CD3 bispecific antibody Tarlatamab was approved on May 16 this year, providing a new treatment option for patients with extensive-stage small cell lung cancer (ES-SCLC).

Although small cell lung cancer accounts for a small proportion of all lung cancer cases, it is one of the most aggressive lung cancer subtypes, and patients urgently need new treatments. We hope that more pharmaceutical companies can continue to make breakthroughs in this field and bring hope to patients.

In this process, domestic pharmaceutical companies will not be absent.

https://mp.weixin.qq.com/s/FCVnqjR4N4Ngxv1jbPYxQA